Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

Silence Therapeutics plc (NASDAQ:SLN), a biotechnology company specializing in RNA therapeutics, stands at a crucial juncture ...

Discover the importance of vision, genetic eye disorders, and RNA-based therapies for precision treatment in India and ...

Akribion Therapeutics ("Akribion"), the early-stage biotech developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announces its exit from stealth and the ...

PORTLAND, IN, UNITED STATES, January 28, 2025 /EINPresswire / -- The RNA based therapeutics has been explored as a promising treatment option for the diseases which are difficult to treat. Development ...

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that Cohort 3 of its Phase 1 clinical trial ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

No significant safety or dose limiting toxicities reported PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results BOSTON, Feb. 6 ...

Researchers at Tel Aviv University have achieved a breakthrough in drug delivery: they have successfully transported lipid ...

Camp4 Therapeutics Corporation’s CAMP share price has dipped by 18.47%, which has investors questioning if this is right time to buy.